]>
IRCT2014031216969N1 IRCT 2014-07-31 Vice Chancellor for Development, Research and Technology of Ahvaz Jondishapour University of Medical Effect of N-Acetylcysteine in hemodialysis patients Effect of N-Acetylcystein on serum Malondialdehyde in comparison with placebo in chronic hemodialysis patients 2014-04-21 anticipated 60 Complete https://irct.ir/trial/15737 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention. 2 Condition 1: Hemodialysis patients. Condition 2: Hemodialysis patients. Condition 3: Hemodialysis patients. Intervention 1: Intervention group: N-acetylcysteine with the trade name Fluimucil, as 600 milligram tablet, made by Swiss Zambon Svizzerasa company, given twice daily (every 12 hours), per oral for 6 weeks. Intervention 2: Control group: Placebo as 600 milligram tablet, twice daily, every 12 hours, per oral for 6 weeks, made from micro-crystalline cellulose, lactose, corn starch, talk (2% of total tablet weight) which made in pharmacology school of Ahvaz Jondishapour University of Medical Sciences.
public Ali Javaherforoushzadeh
Golestan St. Golestan Hospital, Internal Medicine ward
Ahvaz Iran (Islamic Republic of) 6153715794 +98 61 1374 3013 Ali_javaherforoush@yahoo.com; Javaherforoushzadeh.a@ajums.ac.ir Ahvaz Jondishapour University of Medical Sciences scientific Shokouh Shayanpour
Azadegan St. Imam khomeyni Hospital, Nephrology ward
Ahvaz Iran (Islamic Republic of) 6153715794 +98 61 1374 3013 Dr.shayanpour@yahoo.com; shayanpour.sh@ajums.ac.ir Ahvaz University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: 1) all of the chronic hemodialysis patients due to end stage renal disease more than 18 years old and at least three months has been past from starting of hemodialysis. Exclusion criteria: 1) Every acute disease leads to hospitalization from one month before trial. 2) Allergy to N-acetylcysteine. 3) Hepatic cirrhosis 4) Using Vitamin E or C or every known antioxidant from two weeks before intervention. 5) congestive heart failure or ejection fraction less than 35%. 6) Non using of N-acetylcysteine or placebo more than 20% of total drug. 16 years 100 years Both N18 N19 N17 Renal failure Renal failure Renal failure Treatment - Drugs Placebo Intervention group: N-acetylcysteine with the trade name Fluimucil, as 600 milligram tablet, made by Swiss Zambon Svizzerasa company, given twice daily (every 12 hours), per oral for 6 weeks. Control group: Placebo as 600 milligram tablet, twice daily, every 12 hours, per oral for 6 weeks, made from micro-crystalline cellulose, lactose, corn starch, talk (2% of total tablet weight) which made in pharmacology school of Ahvaz Jondishapour University of Medical Sciences. Serum Malondialdehyde. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: With malondialdehyde kit spectrophotometry method in mmol/lit. Itching. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: Visual. Vice Chancellor for Development, Research and Technology of Ahvaz Jondishapour University of Medical Approved 2013-09-23 Ethics committee of Ahvaz Jondishapour University of Medical Sciences Vice chancellery for Development, Research and Technology Ahvaz Jondishapour University of Medical Sciences, university city, Golestan St. Ahvaz Iran (Islamic Republic of)